Rapport Therapeutics, Inc. RAPP 深 沪
等待开盘 09-04 09:30:00 美东时间
15.04
-1.330
-8.12%
华盛通- 最 高16.98
- 今 开15.53
- 成交量 20.64万股
- 最 低 14.8412
- 昨 收 16.37
- 总市值 5.49亿
- 52周最高 29.74
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 6.43
- 委 比 -37.37%
- 总股本 3649.79万
- 历史最高 29.74
- 量 比 0.52
- 振 幅 13.07%
- 历史最低 6.43
- 每 手 1
- 风险率 5.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phibro Animal Health, Pure Storage, Snowflake, Build-A-Bear Workshop And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Thursda...
08-28 23:32
Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.85) by 11.45 percent. This is a 55.88 percent increase over losses of $(1.70) per share
08-07 19:16
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
HC Wainwright & Co. Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $31
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $31.
08-06 19:16
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
07-28 20:13
JMP Securities Reiterates Market Outperform on Rapport Therapeutics, Maintains $28 Price Target
JMP Securities analyst Jason Butler reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Market Outperform and maintains $28 price target.
07-08 22:14
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Theriva Biologics (AMEX:TOVX) stock moved upwards by 47.4% to $0.72 du...
06-03 05:05
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Rapport Therapeutics' Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and set to report top-line results in September 2025. The company hosted its first Investor and Analyst Day to discuss clinical pipeline updates, including RAP-219's progress. RAP-219, an AMPA receptor negative allosteric modulator, targets TARPγ8 for neuroanatomical specificity. The trial's interim data show favorable tolerability, with all adverse ev...
06-02 18:45
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
Rapport Therapeutics, a clinical-stage biotech company focused on small molecule precision medicines for neurological and psychiatric disorders, announced that its management will participate in two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York City on June 4, 2025, and the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025. Live and archived webcasts of the fireside chats will ...
05-27 11:00
Rapport Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.76) by 10.53 percent.
05-08 19:15
